SEC Form 4 · accession 0000357097-16-000125
Fibrocell Science, Inc. · FCSC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Pernock
Officer — Chairman and CEO · Director
Period of report
Mar 1, 2016
Accepted (ET)
Mar 2, 2016 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000357097
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2,F1 | $2.27 | Mar 1, 2016 | A | 425,000 | A | — | Mar 1, 2026 | Common Stock | 425,000 | 425,000 | D |
Explanation of responses
- F1The options set forth in this table vest as follows: 106,250 vesting on March 1, 2017 and 318,750 vesting in 12 equal quarterly installments beginning on June 1, 2017 and ending on March 1, 2020, subject to the grantee's continued service.
- F2The options were issued in connection with the reporting person's employment service to the Company.